期刊文献+

Chinese experts' consensus on diagnosis, prevention, and treatment of chemotherapyinduced hepatotoxicity 被引量:1

Chinese experts' consensus on diagnosis, prevention, and treatment of chemotherapyinduced hepatotoxicity
下载PDF
导出
摘要 Overview Drug-induced liver injury(DILI)due to acetaminophen overdose and idiosyncratic drug reactions usually occurs 5–90 days after exposure to the causative drug.Ninety percent of DILI cases are acute.As one of the most common non-infectious liver diseases,DILI represents a growing challenge for clinicians.According to data from WHO[1],DILI is the fifth leading cause of liver disease mortality.In China,DILI accounts for 1%–5%of hospitalized patients with liver diseases,10%of patients Overview Drug-induced liver injury (DILI) due to acetamino- phen overdose and idiosyncratic drug reactions usually occurs 5-90 days after exposure to the causative drug. Ninety percent of DILI cases are acute. As one of the most common non-infectious liver diseases, DILI represents a growing challenge for clinicians. According to data from WHO , DILI is the fifth leading cause of liver disease mortality. In China, DILI accounts for 1%-5% of hospitalized patients with liver diseases, 10% of patients with acute hepatitis, and 12.2% of patients with fulminant hepatitis .
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2015年第1期32-36,共5页 中德临床肿瘤学杂志(英文版)
  • 相关文献

参考文献14

  • 1Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. Lancet, 2010, 376: 190-201.
  • 2Chen WC. Concern on drug-induced hepatotoxicity. Liver, 2006, 11: 301-302.
  • 3Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver in- jury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol, 2013, 25: 825-829.
  • 4Petronijevic M, Ilic K. Associations of gender and age with the report- ing of drug-induced hepatic failure: data from the VigiBase. J Clin Pharmacol, 2013, 53: 435-443.
  • 5Song PG. Monitoring serum biomarker for liver function. Chin J Clin Hepatol (Chinese), 2003, 19: 195-197.
  • 6FDA, Guidance for industry: Drug-induced liver injury: Premarketing Clinical Evaluation 2009. Available at: http://www.fda.gov/downloads/ drugs/Guidance Compliance Regulatory Information/Guidances/ UCM174090.pdf.
  • 7Hutchinson TA, Lane DA. Assessing methods for causality assess- ment of suspected adverse drug reactions. J Clin Epidemiol, 1989, 42: 5-16.
  • 8Fontana R J, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and con- duct. Drug Saf, 2009, 32: 55-68.
  • 9Fontana R J, Seeff LB, Andrade R J, et al. Standardization of nomen- clature and causality assessment in drug-induced liver injury: summa- ry of a clinical research workshop. Hepatology, 2010, 52: 730-'742.
  • 10Ding TY, Jiang PC. Modern treatment for acute liver function failure. Chin J Hepato Surg (Chinese), 2006, 12: 649-653.

同被引文献3

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部